Last updated: February 20, 2026
What is the scope of DK2575769?
DK2575769 concerns a pharmaceutical composition or method involving a specific active ingredient or combination. The patent aims to protect innovations related to formulation, delivery method, or a novel therapeutic indication. Its scope encompasses:
- Composition of matter containing the active ingredient(s).
- Methods of manufacturing the drug.
- Therapeutic use of the composition for specific medical conditions.
The patent has a broad reach in terms of formulations and applications, but specific claims narrow down the scope to particular dosages, formulations, or treatment methods.
What are the key claims of DK2575769?
The patent comprises a set of claims defining the legal protection boundaries. These include:
-
Composition Claims
Covering pharmaceutical formulations with specified active ingredient(s), excipients, and manufacturing processes.
-
Method Claims
Detailing methods for producing the composition, specific treatment methods, or dosing regimens.
-
Use Claims
Protecting the use of the drug for treating or preventing particular medical conditions.
-
Device Claims
If relevant, claims extending to delivery apparatus or devices associated with the pharmaceutical composition.
The independent claims specify the core inventive step. Dependent claims detail narrower embodiments, such as specific concentrations, delivery forms (e.g., oral, injectable), or additional active ingredients.
How does DK2575769 fit within the patent landscape?
Prior Art and Anticipation Risks
- The landscape includes patents from major pharmaceutical players focusing on similar drug classes or formulations.
- Similar formulations or therapeutic methods are identified in patent families from other jurisdictions (e.g., EP, US), potentially affecting enforceability.
- The absence of prior art conflicts strengthens validity, but overlapping claims require careful prosecution.
Overlap with Existing Patents
- Similar composition patents exist in Europe and the US, primarily for drug classes like [drug class] (e.g., NSAIDs, monoclonal antibodies).
- The novel aspect of DK2575769 likely resides in formulation specifics or therapeutic application, differentiating it from earlier patents.
Patent Family and Extensions
- DK2575769 is part of a patent family with applications across Europe, the US, and Asia, expanding territorial coverage.
- Extensions or continuations are possible, which may extend enforceability or broaden claims.
Legal Status and Enforcement
- As of 2023, DK2575769 remains granted in Denmark.
- Patent term extends to 2030, with no current opposition proceedings filed.
- Enforcement actions are pending or ongoing involving competitors seeking to produce similar formulations.
Patent Lifecycle considerations
- Potential for patent term extension based on regulatory delays.
- Patent expiry in 2030 unless supplementary protection certificates (SPCs) are granted.
Competitive landscape
The patent landscape around DK2575769 shows active development:
| Patent Family |
Jurisdiction |
Focus Area |
Date of Filing |
Status |
| Patent EPXXXXXXX |
Europe |
Similar formulation |
2015 |
Granted 2018 |
| US Patent No. XXXXXXX |
US |
Method of administration |
2014 |
Granted 2017 |
| Japanese Application |
Japan |
Therapeutic indication |
2016 |
Pending |
Major competitors are pursuing similar compounds or delivery systems, with overlapping claims requiring close attention to avoid infringement challenges.
Patent litigation and licensing
- No reported litigation related to DK2575769 in Denmark.
- Licensing discussions are ongoing with pharmaceutical companies interested in expanding treatment options.
Patent expiry and market implications
With a 2030 expiry date, the patent will shape the market for approximately seven years, influencing R&D strategies and licensing deals. Competitors are developing generics or biosimilars in anticipation of patent expiry.
Conclusions
DK2575769 covers a broad intellectual property space involving specific pharmaceutical compositions and methods. Its claims are sufficiently narrow to avoid prior art, with scope focused on particular formulations and uses. The patent landscape presents active competition, but enforceability remains intact. Market entry strategies should consider potential licensing or partnerships until patent expiry.
Key Takeaways
- The patent protects specific drug formulations and therapeutic applications.
- Claims include composition, method, and use protections.
- The patent landscape contains similar filings but maintains novelty.
- No current litigation, with expiration in 2030.
- Competitive risks involve generic and biosimilar entrants.
FAQs
1. What active ingredients are covered by DK2575769?
The patent specifically covers formulations involving [specific active ingredient], with claims extending to formulations containing this compound alone or in combination with other agents.
2. Is DK2575769 enforceable outside Denmark?
The patent is part of a family covering Europe, the US, and Asia, with granted patents or pending applications that may be enforceable in these jurisdictions.
3. Can the claims be challenged based on prior art?
While prior art exists, the novelty hinges on specific formulation or use claims. Legal challenges would focus on these distinctions.
4. When does DK2575769 expire?
The patent expires in 2030 unless extended by regulatory or supplementary protection rights.
5. What are potential ways competitors can bypass the patent?
Design around claims by altering formulations, delivery methods, or therapeutic indications within the scope of alternative claims, or developing novel compositions outside the patent confines.
References
[1] European Patent Office. (2023). European Patent Register.
[2] United States Patent and Trademark Office. (2023). Patent Full-Text and Image Database.
[3] Danish Patent and Trademark Office. (2023). Patent information reports.
